Summary
7.60 0.14(1.81%)01/16/2026
Fennec Pharmaceuticals Inc. (FENC)
FENC reported last earnings on 2025-11-13 after the market. An EPS of $-0.02 was observed compared to an estimated EPS of $-0.08, resulting in a surprise value of $0.06. A revenue of $12 million was observed compared to an estimated revenue of $14 million, resulting in a surprise value of $-2 Million.
Fennec Pharmaceuticals Inc. (FENC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.81 | -2.81 | -9.86 | -8.09 | -2.21 | 40.46 | 0.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Buy |
| ROA | Strong Sell |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 7.60 | |
| Open | 7.46 | |
| High | 7.63 | |
| Low | 7.35 | |
| Volume | 73,661 | |
| Change | 0.14 | |
| Change % | 1.81 | |
| Avg Volume (20 Days) | 169,578 | |
| Volume/Avg Volume (20 Days) Ratio | 0.43 | |
| 52 Week Range | 4.92 - 9.92 | |
| Price vs 52 Week High | -23.44% | |
| Price vs 52 Week Low | 54.37% | |
| Range | 0.00 | |
| Gap Up/Down | -0.18 | |
Profitibility | ||
| Market Capitalization (Mln) | 218 | |
| Revenue per share | 1.3909 | |
| Net Income per share | -0.2488 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -30.5011 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
12/26 17:44 EST - globenewswire.com
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000...
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000...
12/22 03:30 EST - defenseworld.net
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of “Hold” by Analysts
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation...
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of “Hold” by Analysts
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation...
12/21 22:01 EST - seekingalpha.com
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy...
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy...
12/09 07:00 EST - globenewswire.com
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
12/02 11:56 EST - feeds.benzinga.com
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
12/02 07:01 EST - globenewswire.com
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) –
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively) –
11/30 02:10 EST - defenseworld.net
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating...
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating...
11/26 05:59 EST - globenewswire.com
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on...
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on...
11/19 07:03 EST - globenewswire.com
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
RESEARCH TRIANGLE PARK, N. C. , Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC) (TSX: FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec's outstanding convertible notes issued to Petrichor...
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
RESEARCH TRIANGLE PARK, N. C. , Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC) (TSX: FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec's outstanding convertible notes issued to Petrichor...
11/17 16:15 EST - globenewswire.com
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which...
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which...
11/13 23:11 EST - globenewswire.com
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a...
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a...
11/13 23:07 EST - globenewswire.com
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a...
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a...
11/13 18:11 EST - zacks.com
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.21 per share a year ago.
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.21 per share a year ago.
11/13 16:08 EST - globenewswire.com
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public...
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public...
10/30 11:07 EST - zacks.com
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10/15 05:20 EST - zacks.com
New Strong Sell Stocks for Oct. 15th
FENC, BABA and ALCO have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2025.
New Strong Sell Stocks for Oct. 15th
FENC, BABA and ALCO have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2025.
09/19 10:46 EST - zacks.com
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to Adherex Technologies stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to Adherex Technologies stock based on the movements in the options market lately.
08/19 15:34 EST - seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
Market News
×
Loading news…